Devonian Health Group Inc Ordinary Shares - New GSD
News
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay
Devonian Health Group Anticipates to Commence Trading on the NYSE American
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years
